The PI3K–Akt pathway is a highly crucial pathway in cancer development,[40] with its alterations observed in more than 70% of breast tumors; thus, it represents a significant therapeutic target against BC.[41] Therefore, one of the potential therapeutic strategies against BC is to inhibit the estrogen signaling pathway (estrogen production blockage or ER function inhibition). This evidence concerns the gene ESR1 and breast neoplasm.